1. Generics Bulletin

USMCA Signed Into Law In US

Enactment Of ‘Fixed’ USMCA Welcomed By AAM

 
• By Dave Wallace

The US Association for Accessible Medicines has welcomed the final action needed for the US-Mexico-Canada trade agreement to become US law.

Signing
The USMCA has been signed into US law • Source: Shutterstock

The US-Mexico-Canada trade agreement has now become law in the US after being signed by president Donald Trump. Replacing the previous North American Free Trade Agreement, the USMCA deal – sometimes referred to as ‘NAFTA 2.0’ – sets a “new gold standard for free trade agreements,” according to the US Association for Accessible Medicines.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Generics Bulletin

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch

 
• By Dean Rudge

Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.